Showing 5621-5630 of 8845 results for "".
- Largest Psoriasis Meta-Analysis to Date Yields New Genetic Clueshttps://practicaldermatology.com/news/largest-psoriasis-meta-analysis-to-date-yields-new-genetic-clues/2458176/A new meta -analysis identifies 16 additional genetic markers that may help researchers get closer to understanding how — and why — psoriasis develops. University of Michigan researchers, working with partners across the globe, published the work in
- Tweaking TWEAK May Cool Inflammation in Pso and ADhttps://practicaldermatology.com/news/research-breakthrough-tweak-implicated-in-psoriasis-ad/2458178/New research pinpoints a common driver of skin inflammation in both psoriasis and atopic dermatitis. The findings, published in the May 22, 2017 issue of Nature Communications, showed that TWEAK, a protein related to
- Statement from AAD President Henry W. Lim, MD, FAAD, on the Safety of Sunscreenhttps://practicaldermatology.com/news/statement-from-aad-president-henry-w-lim-md-faad-on-the-safety-of-sunscreen/2458179/“The American Academy of Dermatology wants to emphasize that sunscreen remains a safe, effective form of sun protection. As one component of a daily sun-protection strategy, sunscreen is an important tool in the fight against skin cancer, including melanoma, the deadliest form of skin cance
- SkinCeuticals Study Finds Antioxidants Protect Against Atmospheric Skin Aginghttps://practicaldermatology.com/news/skinceuticals-study-finds-antioxidants-protect-against-atmospheric-skin-aging/2458181/Exposure to ozone pollution zaps our collagen supply, according to new research from SkinCeuticals in partnership with Professor Giuseppe Valacchi from the University of Ferrara, Italy. After exposure to 0.8ppm ozone, collage
- Valeant Dermatology Announces New Senior Leadership Team in Advance of SILIQ Launchhttps://practicaldermatology.com/news/valeant-dermatology-announces-new-senior-leadership-team-in-advance-of-siliq-launch/2458182/Valeant Dermatology announced a new senior leadership team, led by Bill Humphries, executive vice president and group chairman. The team includes Michael McMyne, vice president of sales; Stacey Williams, vice president of marketing; Charles Hahn,
- The American Society for Laser Medicine and Surgery Names New Officershttps://practicaldermatology.com/news/the-american-society-for-laser-medicine-and-surgery-names-new-officers/2458185/The American Society for Laser Medicine and Surgery (ASLMS) introduced Mathew M. Avram, MD, JD, as its new President at the Annual Conference in April. Dr. Avram succeeds Kristen M. Kelly, MD, who now serves as the Society’s Past President. The 2017-18 ASLMS Executive Committee also i
- CVS Pharmacy's New Long Live Skin Campaign Aims to Increase Awareness of Skin Healthhttps://practicaldermatology.com/news/cvs-pharmacys-new-long-live-skin-campaign-aims-to-increase-awareness-of-skin-health/2458183/CVS Pharmacy, the retail division of CVS Health, is rolling out a new multi-platform Long Live Skin campaign to increase awareness about skin health, sun safety and proper skincare. The Long Live Skin Campaign kicks off today online&nbs
- BERG and debra of America Partner to Raise Awareness of EBhttps://practicaldermatology.com/news/berg-and-debra-of-america-partner-to-raise-awareness-of-eb/2458184/Biopharmaceutical company BERG and the non-profit patient advocacy group Dystrophic Epidermolysis Bullosa Research Association of America (debra of America) are partnering up to help patients and families affecte
- Study: Smiling May Not Make Us Appear Younger After Allhttps://practicaldermatology.com/news/study-smiling-may-not-make-us-appear-younger-after-all/2458186/Conventional wisdom suggests that smiling makes you appear younger, but researchers at Ben-Gurion University of the Negev in Israel beg to differ. People who smile are actually perceived as older than those with a deadpan or surprised expression, according
- FDA Accepts Aclaris Therapeutics' NDA for Topical Treatment of Seborrheic Keratosishttps://practicaldermatology.com/news/fda-accepts-aclaris-therapeutics-nda-for-topical-treatment-of-seborrheic-keratosis/2458188/The FDA has accepted Aclaris Therapeutics' New Drug Application (NDA) for A-101 40% topical solution, an investigational drug for the potential treatment of seborrheic keratosis (SK). The NDA acceptance by the FDA in its 74-day letter indicates that the application is sufficiently complete to